Takasago International Corporation

The Doshisha

National Center for Geriatrics and Gerontology

Tetsuo Ota

Noboru Sayo

Hachiro Sugimoto

Yoshikazu Inoue

Kazushi Mashima

Kyoko Tamao

Rie Tokizane

Yasuo Ihara

Hidemasa Takaya, Deceased

Tomohiro Miyasaka

Koji Inagaki

Yuki Shinzaki

Yohei Oe

Akihiko Takashima

Yoshiyuki Soeda

A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).

Tau aggregation inhibitor

Disclosed is a ruthenium-phosphine complex represented by formula (I):

Process for preparing ruthenium-phosphine complex

An optically active 2-diphenylphosphinomethyl-2'-diphenylphosphinyl-1,1'-binaphthalene derivative represented by the following general formula (I) ##STR1## wherein R represents a phenyl group, a tolyl group, an anisyl group or a chlorophenyl group, and a process for the production of optically active substances in which the above compound and a transition metal compound are used. The asymmetric diphosphine of the present invention is related to the creation of novel compounds, which is excellent as a ligand for asymmetric synthesis use. When the above compound is used together with a transition metal compound such as of ruthenium, rhodium or the like, it shows markedly excellent properties as the catalyst of asymmetric hydrogenation and the like reactions, in terms of selectivity, conversion ratio, catalytic activity and the like.

Optically active asymmetric diphosphine and process for producing

Growing community of inventors

Kyoto, Japan

Tetsuo Ota